BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority of BRAFV600 Mutated Cancers
Results of the NCI-MATCH Trial Subprotocol H
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Results of the NCI-MATCH Trial Subprotocol H
Arsenic trioxide medac is a generic of Trisenox which has been authorised in the EU since 2002
Efficacy of tafasitamab-cxix with lenalidomide was evaluated in L-MIND study
Biosimilar bevacizumab received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and cervical carcinoma
An experience of the Drug Development Department of the Gustave Roussy
Big analysis delineated two subsets of patients with distinct phenotypes and outcomes
Efficacy was investigated in the IMspire150 study
Approval is based on the findings from the ZUMA-2 trial
Acalabrutinib, a Bruton tyrosine kinase inhibitor, is intended for the treatment of chronic lymphocytic leukaemia
First antibody-drug conjugate for multiple myeloma patients with limited treatment options
It is intended for the treatment of adult patients with unresectable or metastatic GIST harbouring the PDGFR alpha D842V mutation
New indication concerns first-line treatment of adults with extensive-stage small cell lung cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.